Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBITDA Margin: 2012-2024

Historic EBITDA Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to 28.06%.

  • Amphastar Pharmaceuticals' EBITDA Margin fell 1664.00% to 13.20% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.73%, marking a year-over-year decrease of 888.00%. This contributed to the annual value of 28.06% for FY2024, which is 251.00% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its EBITDA Margin stood at 28.06% for FY2024, which was down 8.20% from 30.57% recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' EBITDA Margin registered a high of 30.57% during FY2023, and its lowest value of 3.13% during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median EBITDA Margin value was 28.06% (recorded in 2024), while the average stood at 26.73%.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' EBITDA Margin soared by 1,283bps in 2021, and later slumped by 251bps in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBITDA Margin (Yearly) stood at 3.13% in 2020, then spiked by 1,283bps to 15.96% in 2021, then spiked by 558bps to 21.54% in 2022, then soared by 903bps to 30.57% in 2023, then slumped by 251bps to 28.06% in 2024.